Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood

BMC Dermatology

Volumn 4, Issue , 2004, Pages

  Boms, Stefanie ^a   Gambichler, Thilo ^b   Freitag, Marcus ^a   Altmeyer, Peter ^a   Kreuter, Alexander ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b OLDCHURCH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; EMOLLIENT AGENT; GLUCOCORTICOID; NYSTATIN; PIMECROLIMUS; POLIDOCANOL; STEROID; TACROLIMUS; CALCINEURIN; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ANUS; ARTICLE; CASE REPORT; CHILD; CHILDHOOD; CREAM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; GENITAL SYSTEM; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LICHEN SCLEROSUS ET ATROPHICUS; OUTCOMES RESEARCH; PAIN; PREPUBERTY; PRURITUS; REMISSION; SIDE EFFECT; ANUS DISEASE; DRUG ANTAGONISM; INTRADERMAL DRUG ADMINISTRATION; MALE; OINTMENT; TREATMENT OUTCOME; VULVA DISEASE;

ADMINISTRATION, CUTANEOUS; ANUS DISEASES; CALCINEURIN; CHILD; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LICHEN SCLEROSUS ET ATROPHICUS; MALE; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME; VULVAR DISEASES;

EID: 10444238434     PISSN: 14715945     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-5945-4-14     Document Type: Article

References (14)

1. Meffert JJ, Davis BM, Grimwood RE: Lichen sclerosus. J Am Acad Dermatol 1995, 32:393-416.
2. Carli P, Cattaneo A: Skin immune system involvement as a clue to the pathogenesis of lichen sclerosus. Eur J Dermatol 1994, 4:572.
3. Marren P, Millard PR, Wojnarowska F: Vulvar lichen sclerosus: lack of correlation between duration of clinical symptoms and histological appearances. J Eur Acad Dermatol Venereol 1997, 8:212-216.
4. Powell J, Wojnarowska F, Winsey S, Marren P, Welsh K: Lichen sclerosus premenarche: autoimmunity and immunogenetics. Br J Dermatol 2000, 142:481-484.
5. Smith YR, Haefner HK: Vulvar lichen sclerosus: pathophysiology and treatment. Am J Clin Dermatol 2004, 5: 05-25.
6. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin M-E, Burtin P, Stephenson TJ: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003, 88:969-973.
7. Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stücker M, Bader A, Altmeyer P, Freitag M: Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004, 51:407-410.
8. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RGB, Cherill R, Marshall K, Bush C, Gräber M: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002, 46:495-504.
9. Böhm M, Frieling U, Luger TA, Bonsmann G: Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003, 139:922-924.
10. Kunstfeld R, Kirnbauer R, Stingl G, Karlhofer FM: Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol 2003, 139:850-852.
11. Assmann T, Becker-Wegerich P, Grewe M, Megahed M, Ruzicka T: Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol 2003, 48:935-937.
12. Goldstein AT, Marinoff SC, Christopher K: Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004, 17: 35-37.
13. Ständer S, Luger TA: Antipruritic effects of pimecrolimus and tacrolimus. Hautarzt 2003, 54:413-417.
14. Cattaneo A, Carli P, De Marco A, Sonni L, Bracco G, De Magnis A, Taddei GL: Testosterone maintenance therapy. Effects on vulvar lichen sclerosus treated with clobetasol propionate. J Reprod Med 1996, 41:99-102.